At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Avastin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Avastin in Combination With Docetaxel in Patients With Recurrence of Epithelial Carcinoma of the Ovary/Fallopian Tube/Peritoneum Within 12 Months of Platinum Therapy
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Jul 19, 2007·Updated Feb 6, 2014
In Brief
A Phase 2 clinical trial evaluating Avastin and Docetaxel for Fallopian Tube Cancer and 2 related conditions. Completed, enrolled 45 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the effectiveness of the combination of Avastin and Docetaxel in the treatment of women with platinum sensitive recurrent epithelial ovarian cancer within 12 months of platinum chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Genentech, Inc., Sanofi
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedJul 2007
Primary CompletionOct 2012
TodayJul 2026
First PostedJul 19, 2007
Enrollment StartMar 1, 2007
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 19.0 years ago
Interventions
Avastindrug
Day 1, every 21 day cycle
Docetaxeldrug
Day 1, 8, every 21 day cycle